187 related articles for article (PubMed ID: 9867538)
1. Iron chelation with oral deferiprone in patients with thalassemia.
Nathan DG; Weatherall DJ
N Engl J Med; 1998 Dec; 339(23):1711-2; author reply 1713-4. PubMed ID: 9867538
[No Abstract] [Full Text] [Related]
2. Iron chelation with oral deferiprone in patients with thalassemia.
Tricta F; Spino M
N Engl J Med; 1998 Dec; 339(23):1710; author reply 1713-4. PubMed ID: 9867536
[No Abstract] [Full Text] [Related]
3. Iron chelation with oral deferiprone in patients with thalassemia.
Callea F
N Engl J Med; 1998 Dec; 339(23):1710-1; author reply 1713-4. PubMed ID: 9867537
[No Abstract] [Full Text] [Related]
4. Iron chelation with oral deferiprone in patients with thalassemia.
Stella M; Pinzello G; Maggio A
N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867539
[No Abstract] [Full Text] [Related]
5. Iron chelation with oral deferiprone in patients with thalassemia.
Wonke B; Telfer P; Hoffbrand AV
N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867540
[No Abstract] [Full Text] [Related]
6. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation with oral deferiprone in patients with thalassemia.
Cohen AR; Martin MB
N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
[No Abstract] [Full Text] [Related]
8. Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard MJ; Weatherall DJ
Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
[No Abstract] [Full Text] [Related]
9. Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?
Kowdley KV; Kaplan MM
N Engl J Med; 1998 Aug; 339(7):468-9. PubMed ID: 9700182
[No Abstract] [Full Text] [Related]
10. Deferiprone-induced seizures in a patient with β-thalassemia major.
Mallat NS; Beydoun A; Musallam KM; Koussa S; Taher AT
Blood Cells Mol Dis; 2013 Aug; 51(2):94-5. PubMed ID: 23587452
[No Abstract] [Full Text] [Related]
11. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation with oral deferiprone in patients with thalassemia.
Grady RW; Giardina PJ
N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
[No Abstract] [Full Text] [Related]
13. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
14. Long term deferiprone chelation therapy.
Hoffbrand VA; Wonke B
Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
[No Abstract] [Full Text] [Related]
15. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
16. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
18. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
[TBL] [Abstract][Full Text] [Related]
19. Orally active iron chelators in the treatment of iron overload.
Olivieri NF
Curr Opin Hematol; 1996 Mar; 3(2):125-30. PubMed ID: 9372062
[TBL] [Abstract][Full Text] [Related]
20. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
